Introduction
Sexual dysfunction in patients affected by neurological disorders has many causes. A conceptual model for sexual problems was initially proposed to characterise three levels of influence in patients with multiple sclerosis (MS): primary, secondary and tertiary sexual dysfunction. Actually this model is valid for all neurological patients and should always be included in the diagnostic algorithm to address the appropriate examinations and therapies for sexual dysfunction as well. Primary sexual dysfunction results from neurological lesions directly affecting the neural pathways subserving sexual function. Neurological diseases affecting the cerebrum, brain stem, spinal cord, spinal roots or peripheral nerves including the autonomic nervous system, can alter sexual function [1,2].
Sexual dysfunction includes decreased or loss in libido, painful or uncomfortable genital sensations (burning, tingling, numbness), and/or altered orgasmic response in both women and men. Women may experience decreased vaginal lubrication and dryness, anorgasmia, and low sex drive [3, 4] . Men may have difficulty achieving and/or maintaining an erection, and diminished frequency of ejaculation [5] [6] [7] . Secondary sexual dysfunction arises as a consequence of disability caused by poor bladder and bowel control, fatigue, muscle weakness, spasticity, immobility, tremor, cognitive impairment, and sensory problems. Secondary sexual dysfunction can also be a result of non-neurological co-morbidities, e.g. hypertension, diabetes, depression, hypercholesterolaemia, obesity, and chronic smoking. In addition, medications that are used for the neurological conditions (spasticity, urinary frequency, sensory pain, etc.) and non-neurological co-morbidities (hypertension, diabetes, depression, etc.) can further contribute to secondary sexual dysfunction. Tertiary sexual dysfunction is related to psychological, social and cultural issues that affect sexual response. These variables can include anxiety, low self-esteem, altered marital and family roles, changes in body image, and fear of rejection by the partner [8] [9] [10] [11] . For each individual with a neurological disease, these three levels are interconnected and may fluctuate, interfering with each other continuously throughout life, generating or leading to a worsening of sexual impairments. Before addressing sexual dysfunction in a patient with a neurological disease, attitude towards sex, sexual orientation and cultural influences should be determined. Involvement of the patient's partner is recommended, if appropriate, when the quality of the relationship and the patient/partner needs and expectations of therapy have been assessed. Neurogenic sexual dysfunction often severely disrupts quality of life, so that healthcare professionals must be involved in treating an individual's sexual health [12, 13] . In the present study, we aimed to systematically assess the management of sexual dysfunction due to CNS disorders.
Patients and Methods
This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement [14] . Two authors (M.L and S.M.) independently searched MEDLINE and OVID using the following terms: 'neurogenic sexual dysfunction' (OR) 'neurogenic erectile dysfunction' (OR) 'spinal cord' , 'multiple sclerosis' , 'Parkinson's disease' , 'stroke' , 'epilepsy' , 'spina bifida' (AND) 'sexual dysfunction' (OR) 'erectile dysfunction' (OR) 'sexual function' (AND) 'treatment' . Search criteria were limited to humans, adults, and full-text English articles. All relevant papers published in English from 2004 to 2014 were retrieved. References of selected articles and international guidelines were hand searched to identify additional reports. All identified studies were screened for eligibility, in accordance with the Cochrane Handbook for Systematic Reviews of Interventions [15] . As this systematic review focused on the management of sexual dysfunction due to CNS disorders, studies on patients with peripheral neuropathy or surgical disruption of the genital autonomic nerve supply were excluded as were studies on fertility issues. Data extraction was independently performed by three authors (M.L., S.M., G.L.) followed by crosschecking and clarification of any differences by the senior author (G.D.P.).
Results
The flow diagram of literature searches and results is shown in Fig. 1 . We identified 302 records. In all, 256 reports were assessed for eligibility, with 31 articles finally included in this systematic review.
Men
The assessment of neurogenic erectile dysfunction (ED) is based on various mandatory steps. Overall the assessment criteria stemmed from data on patients with neurogenic ED Full-text articles assessed for eligibility (n = 167)
Full-text articles excluded according to our inclusion criteria:
-No central nervous system n = 65 -No treatment n = 71
Studies included in qualitative synthesis (n = 31) 
PDE5Is Treatment
Men with SCI (Table 1) The clinical efficacy of sildenafil (Viagra Furthermore, the medium-and long-term efficacy of sildenafil and tadalafil has also been documented in follow-ups of up to 10 years [16, 22] .
Significant statistical improvement (P < 0.01) on antegrade ejaculation using question 9 of the IIEF-15 was detected at the end of the clinical trials using tadalafil, vardenafil and sildenafil [25, 29, 31] .
In studies comparing several ED treatments, Del Popolo et al. [17] showed that for patients with SCI tadalafil 10 mg was more effective at 12-24 h after dosing than sildenafil 50 mg.
Moemen et al. [26] evaluated the efficacy, safety and patient preference for different ED treatments. One 20-patient group Table 1 PDE5i results for neurogenic ED in SCI patients. Parkinson's disease One study of Safarinejad et al. [24] was selected according to our criteria. In all, 116 patients in the sildenafil 100 mg group showed a significant increase in the IIEF erectile function score and in the percentage of 'Yes' responses to the Global Efficacy Questions 2 and 3 (P < 0.001) compared with 115 patients in the placebo group. A normal erectile function domain score (≥26) was achieved by 56.9% and 8.7% of the patients in the sildenafil and placebo groups, respectively (P = 0.001).
Side-Effects of PDE5Is
The most common side-effects reported in men with neurogenic ED using PDE5Is were headache and flushing. ) showed statistical improvement in all IIEF-15 domains compared with baseline up to the final 12-month follow-up. Concerning the IIEF-15 erectile function domain their mean score increased from 9.3 to 23.9 at the final follow-up (P < 0.01).
In a prospective randomised, double-blind trial comparing the effects of 3-months anastrazole plus testosterone (18 patients) vs testosterone plus placebo (18 patients) in hypogonadic epileptic men, Herzog et al. [35] found both groups significantly increased their scores (P < 0.001) on the IIEF-5.
Perineal electrostimulation
In a study by Shafik et al. [36] , 18 patients with MS with neurogenic ED showed a substantial rise in intracavernosal pressure during repetitive percutaneous perineal electrostimulation lasting from 15 to 20 min (P < 0.05).
Neuromodulation
In two studies in which men with incomplete SCI were submitted to a monolateral sacral S3 electrode implant for their neurogenic LUTS (NLUTS) the evaluation of erectile function was assessed at baseline and in the follow-ups after permanent sacral neuromodulation (SNM) (Medtronic®, Minneapolis, MN, USA) at 3 months and subsequently every 6 months after permanent SNM using the IIEF-5. Scores ≥25%, compared with baseline, of the total IIEF-5 score indicated remarkable enhancement on erectile function, and those patients were considered 'responders' . An IIEF-5 score of ≥22 represents normal erectile function. Overall, 10 of 22 men with incomplete SCI reached and maintained a normal IIEF-5 score for >3 years at the final follow-up. However, four patients were contralaterally re-implanted on the S3 root during follow-up because they had lost clinical voiding and erectile function benefits [37, 38] .
On the contrary, 10 patients with complete lesions according to the AIS had bilaterally implanted sacral S3 lead during their shock phase to prevent neurogenic detrusor overactivity. Two patients reported subjective amelioration on erectile function at 6 and 24 months follow-ups, respectively [39] .
Penile prosthesis
As for penile prosthesis, Zermann et al. [40] showed that sexual intercourse was possible for 77 of 92 patients with SCIs (83.7%) with a mean follow-up of ≈7 years for patients who had exclusively undergone penile prosthesis for ED. Several types of penile prosthesis were used. Only nine patients were included pre-sildenafil release and they were 'non-responders' . During follow-ups, 12 patients (16.3%) did not use the prosthesis for sexual intercourse. They complained about instability of the erect penis or symptoms related to the concord phenomenon.
Women

History
Women with a previous history of sexual dysfunction before their diagnosis of neurological illness were excluded for treatments [32, [41] [42] [43] [44] .
Furthermore, a woman's neurological status had to be stable for ≥6 months before therapy. Only sexually active women were included [32, [41] [42] [43] [44] .
Information regarding the correlation between the use of specific medication for their neurological disease and sexual response was requested: 'not related' , 'partially related' and 'totally related' [44] .
Specific Neurological Assessment
The AIS assessment provided inclusion/exclusion criteria or predictable factors for success on the basis of the level and degree of lesion. Women with the ability to perceive T11-L2 pinprick sensations may have psychogenic genital vasocongestion. Reflex lubrication and orgasm are more prevalent in women with SCI who had preserved the sacral reflex (S2-S5). For those with complete SCI of the sacral segment, arousal and orgasm may be evoked through stimulation of other erogenous zones above the level of lesions such as the breasts, lips, and ears [2, 45] .
Neurophysiological assessment using pudendal and tibial SEPs was reported by one author [42] .
Specific Questionnaires for Assessing Primary Sexual Dysfunction
The tools most used for neurological females were the Female Sexual Function Index (FSFI) and the Sexual Function Questionnaire (SFQ) ( Table 2) . 
Laboratory Investigations
There is no recommended consensus about routine laboratory tests for neurological women with sexual dysfunction. Pregnancy was reported by some authors as an exclusion criterion for treatment [32, 42, 43] .
Treatment Options for Neurogenic Primary Sexual Dysfunction in Females
There are no evidence-based therapeutic options to treat neurological women with sexual dysfunction.
Drug therapy
Dasgupta et al. [42] in a double-blind, randomised, placebo-controlled, crossover study investigated the positive effects on FSFI on women with MS of sildenafil starting with 50 mg and dose adjustment (25-100 mg) for tolerability or greater efficacy. In a double-blind placebo-controlled, flexible-dose study with a larger cohort of females with SCIs, Alexander et al. [41] showed a lack of clinically meaningful benefits with sildenafil.
Two phase III, multicentre, randomised, placebo-controlled clinical trials evaluating the use of fampridine sustained-release tablets to treat spasticity in females with incomplete chronic SCI did not show an amelioration in female sexual function [32].
Gil-Nagel et al. [44] in an open, prospective, multicentre study showed that females naïve to other anti-epileptic drugs who initiated lamotrigine for various seizure types gained more benefits in sexual function than women who switched to lamotrigine from previous anti-epileptic drugs inducing the hepatic P450 enzyme such as valproate, carbamazepine and phentyoin.
Neuromodulation
Female patients who underwent SNM for NLUTS were also evaluated for sexual dysfunction.
Lombardi et al. [43] , in a 2-year follow-up after permanent SNM, reported that 36.5% of females with SCI and sexual dysfunction obtained positive effects on sexual response and showed a remarkable concomitant improvement through the Female Sexual Distress Scale (FSDS) questionnaire, which measures sexually related distress.
Discussion
Many individuals with neurological disorders have impaired sexual function that require various steps to manage challenges, starting with an accurate assessment of the disorder such as to tailor diagnostic investigations and treatments to each individual. Ideally, due to the complexity of sexual issues for neurological patients, management should be based on multidisciplinary teamwork starting at the onset of the neurological diagnosis and lasting for life. Scheduled follow-ups at rehabilitation centres or in neurological departments must comprehend sexuality issues. Therefore, cooperation among medical specialists and other health professionals is needed [10, 46] . Although the PLISSIT (Permission, Limited Information, Specific Suggestions, and Intensive Therapy) model, which has health professionals actively addressing primary, secondary, and tertiary factors, has been successfully applied only to patients with SCI, it could be useful for all neurological patients [2] .
No data have been found about treatment of sexual dysfunction in spina bifida adults over recent decades. One possible reason may be the difficulty in evaluating their sexual dysfunction and its impact on their quality of life, due also in part to psychogenic issues. Adolescents with spina bifida cannot have proper knowledge of sexuality because they have never experienced it. Ideally an appropriate sex education starting in childhood and taking into account all aspects related to sexuality should be provided for their sexual health [47] [48] [49] .
Neuro-physiological investigations are not mandatory for neurological patients before starting sexual dysfunction treatment, neither to determine the severity of ED in men, nor the type and degree of female sexual dysfunction. Moreover, their role as predictive factors for the success of ED and female sexual dysfunction therapies is controversial. A hypothesis, especially relevant for women, is that several neurophysiological tests do not examine certain aspects that may influence female sexual response such as marital satisfaction and marital communication, according to the Basson et al. [50] model.
For the evaluation of blood sexual hormones, most studies on males with neurogenic ED performed hormonal assessment before oral treatments at baseline in order to avoid ED related to sexual hormonal abnormalities [16, [20] [21] [22] [23] 25, 26] .
It is well documented that neurological patients have higher risks of hormonal modifications (mainly low levels of testosterone) compared with the non-neurological population [51] . Checking the hormonal status may discriminate between possible therapies and help to decide appropriate treatment. In women of reproductive age, a correlation between female sexual dysfunction and blood sexual hormonal status is not demonstrated. However, the interaction between the CNS and female sexual function hormones and their aetiological roles in sexual dysfunction is complex. A strategy that includes blood sexual hormonal assessment and subsequent hormonal replacement is still undefined [52, 53] . Both testosterone and oestriol have been found to induce anti-inflammatory, as well as neuroprotective effects in MS [53] . Furthermore, oestrogen replacement probably benefits women with SCI more than it does non-neurological patients. In fact, oestrogens prevent osteoporosis, which is accelerated in the paralyzed and not charged areas [52, 54] .
Despite those potential benefits, there are some negative aspects to using hormonal therapies on neurological patients. For example, females with an absence or reduction of lower limb motility may have a high risk of thromboembolism. Again, the use of sexual hormones on females with catamenial epilepsy may increase the rate of seizures [1,4].
For specific neurogenic ED treatments, the existing body of evidence suggests that the PDE5Is sildenafil, vardenafil and tadalafil are first-line therapies for patients with SCI. However, no information has been reported to date on the efficacy/safety of the newer PDE5Is, avanafil and mirodenafil. Data on PDE5Is used on other patients with neurogenic ED are partial or missing. For male patients with Parkinson's disease and MS, the existing results are encouraging. For other central neurological diseases, such as MSA and epilepsy, data seems to suggest avoiding the use of PDE5Is as a first-line treatment for neurogenic ED due to possible severe AEs. Hussain et al. [55] showed that three of six patients with MSA had a severe blood pressure plunge 1 h after sildenafil was administered (systolic blood pressure <65 mmHg and diastolic blood pressure <55 mmHg). Instead, information is currently insufficient to speculate whether PDE5Is may prompt epileptic seizures in previous non-epileptic subjects, and whether they may increase ictal episodes in pharmacologically well-controlled seizure disorders [55] [56] [57] . However, the choice of anti-epileptic drug seems to be one cause of sexual dysfunction that is modifiable. Sexual dysfunction is related to anti-epileptic drugs that induce the hepatic P450 enzyme with a progressive increase of sex-hormone-binding-protein levels and consequently a decrease in free, bioavailable testosterone [58] . This may explain the improvement in epileptic hypogonadic men on sexual function treated with testosterone [35] .
Similarly, women who had previously used anti-epileptic drugs inducing cytochrome P450 improved sexual function less than women who started lamotrigrine as first monotherapy [59, 60] .
International guidelines recommend ICI vasoactive drugs as a second-line treatment [2] . However, data on the efficacy of ICI vasoactive medications for neurogenic ED are lacking following the release of PDE5Is. Thus, no studies have been done that exclusively include PDE5I non-responders or offer different possible solutions as second-line treatment, alone or combined (vacuum device, testosterone, ICI plus PDE5Is, or PDE5Is plus testosterone).
In addition, there are no data on the daily use of PDE5Is as penile rehabilitation for patients with a CNS disorder, compared with those with a peripheral neurological disease, to favour the enhancement of angiogenesis and neurogenesis of corpora cavernosa function [61] .
For specific treatments for primary female sexual dysfunction, data are poor and controversial. Particularly, sildenafil has been tested only on female patients with MS and SCI for possible benefits in arousal response, although these findings need to be confirmed with larger cohorts [41, 42] .
A common treatment for NLUTS for both genders is permanent SNM. The presence and impact of this therapy on sexual function has been evaluated by validated questionnaires at baseline and during follow-up after permanent SNM implantation in the medium-and long-term [43, 52, 56] .
The objective assessment of sexual function in a treatment approved for NLUTS is a new strategy of evaluation. Although definitive SNM is not yet indicated for sexual dysfunction, an objective evaluation approach regarding sexual function should be recommended for all neurological patients [37, 38, 43, 62, 63] . The mechanism of SNM on sexual function is unknown, but potential direct mechanisms are possible. Positive findings in neurological females compared with non-neurological patients supported this thesis [43, 63] . Only continual monitoring of patients who have undergone permanent SNM may clarify possible predictable and positive factors on sexual dysfunction, such as stimulation setting parameters [37, 38, 43, 63] .
A similar methodological approach was recently reported on, which evaluated the impact of fampridine (a drug mainly used for lower limb motility) on sexuality, using validated questionnaires for both genders [32] . At the same time, during primary treatment (such as PDE5Is) for sexual dysfunction, objective assessment should also be done to evaluate impact on secondary conditions that may interfere with therapeutic success [64] . This holistic methodology may help to select an appropriate and patient-tailored treatment. Based on the multiple factors that influence neurogenic sexual dysfunction, creating specific questionnaires for these patients is necessary.
Conclusions
Although sexual dysfunction is a major burden for patients with CNS disorders, high-level evidence is only available on PDE5Is that treat ED; well-designed prospective studies are urgently needed for both genders.
